We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 61.50 | 61.00 | 62.00 | 62.00 | 61.50 | 61.50 | 61,694 | 08:00:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 24.48M | -2.7M | -0.0382 | -16.10 | 43.4M |
TIDMTRX
RNS Number : 0742Y
Tissue Regenix Group PLC
10 May 2021
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Director/PDMR Shareholding
Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that on 7 May 2021, David Cocke, Chief Financial Officer, acquired 2,821,000 Ordinary Shares in the Group at a price of 0.64 pence per share for a total consideration of GBP18,054.40.
As a result, David Cocke's beneficial interest in the Company is 2,821,000 Ordinary Shares, representing 0.04% of the total issued share capital.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities / person closely associated ---------------------------------------------------------------- a) Name David Cocke ------------------------ -------------------------------------- 2 Reason for the notification ---------------------------------------------------------------- a) Position/status Chief Financial Officer ------------------------ -------------------------------------- b) Initial notification Initial notification /Amendment ------------------------ -------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---------------------------------------------------------------- a) Name Tissue Regenix Group plc ------------------------ -------------------------------------- b) LEI 213800PNOD5UHQUFJI36 ------------------------ -------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---------------------------------------------------------------- a) Description of the financial Ordinary Shares of 0.1p each instrument, type of instrument ------------------------ -------------------------------------- b) Identification GB00B5SGVL29 code ------------------------ -------------------------------------- c) Nature of the Acquisition of Ordinary Shares transaction ------------------------ -------------------------------------- d) Price(s) and Price Volume volume(s) 0.64p 2,821,000 ---------- ------------------------ -------------------------------------- d) Aggregated information - Aggregated 2,821,000 volume GBP18,054.40 - Price ------------------------ -------------------------------------- e) Date of the 7 May 2021 transaction ------------------------ -------------------------------------- f) Place of the London Stock Exchange, AIM Market transaction ------------------------ --------------------------------------
For more information:
Tissue Regenix Group plc www.tissueregenix.com David Cocke, Chief Financial Officer Via Walbrook PR Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44(0)20 7710 7600 and Broker) Ben Maddison / Alex Price Walbrook PR Ltd Tel: +44 (0)20 7933 8780 Alice Woodings / Paul McManus TissueRegenix@walbrookpr.com
About Tissue Regenix ( www.tissueregenix.com )
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies(R), a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHGIGDUBUBDGBG
(END) Dow Jones Newswires
May 10, 2021 05:00 ET (09:00 GMT)
1 Year Tissue Regenix Chart |
1 Month Tissue Regenix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions